Tocilizumab: its use is suggested only in selected cases, such as in patients with serum interleukin 6 (IL-6) level ten-fold above the upper normal limit or more, elevated D-dimer, thromboelastrometry suggestive of hypercoagulability state and sequential organ failure assessment (SOFA) score (18) ≥4, in addition to no presumed secondary bacterial infection, or liver dysfunction (international normalized ratio – INR >2.0 or total bilirubin – TB >2.0). Here, IL6 is linked to Decreased liver function.